subject area of
- Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum Academic Article
- Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial Academic Article
- Non-Severe Hypoglycemia Risk Difference Between Sulfonylurea and Sodium-Glucose Cotransporter-2 Inhibitors (Sglt2-I) as an Add-On to Metformin in Randomized Controlled Trials Academic Article
- Patient data from routinely collected medical records complement evidence from SGLT2 inhibitor outcome trials Academic Article
- Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes–2015 Interim Update Academic Article
- SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline Academic Article
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels Academic Article